Convergence of biotechnology, diagnostics and therapeutics has the potential to reshape our perspectives on how health care is delivered, resulting in earlier diagnosis, more patient-centered care, preventative medicine, and safer, more effective treatment. Many analytic instrument companies have already entered the molecular diagnostics market through acquisitions and alliances for co-promotion and/or co-development. Companies whose customers have traditionally been academic, commercial or institutional labs face a particularly steep learning curve. In order to be successful in molecular diagnostics, companies need to
expand their core capabilities in commercial operations, as well as develop and grow new capabilities that are key differentiators to meeting the needs of the molecular diagnostics customer.

• Educate on the opportunity and implications of the emerging commercialization of a broad set of molecular diagnostics and theranostics
• Discuss specific challenges of transforming a traditionally science-focused product into one that be applied a broader commercial audience
• Explore the latest innovations in commercial operations and alliance management on both sides of the molecular diagnostics and biotechnology "divide"